Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramucirumab + tusamitamab ravtansine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ramucirumab + tusamitamab ravtansine is a combination therapy being investigated for various cancers. Tusamitamab ravtansine is an antibody-drug conjugate (ADC) that targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers a cytotoxic maytansinoid payload. Ramucirumab is an antiangiogenic agent. The combination has shown encouraging antitumor activity in clinical trials, with an observed objective response rate (ORR) of 22.6% in non-squamous non-small cell lung cancer (NSq NSCLC) patients, including one complete response, and a median duration of response of 11.1 months.
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on ramucirumab + tusamitamab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramucirumab + tusamitamab ravtansine.